NS-11821

NS-11821, or NS11821 is a GABA A receptor positive allosteric modulator and nonbenzodiazepine which was under development for the treatment of anxiety disorders and CNS disorders but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

NS-11821, or NS11821 is a GABA A receptor positive allosteric modulator and nonbenzodiazepine which was under development for the treatment of anxiety disorders and CNS disorders but was never marketed. It is taken orally. The drug is a subunit-selective partial positive allosteric modulator of the GABA A receptor.

More specifically, it shows affinity (K i ) values of 1.6 nM at α 1 , 9.7 nM at α 2 , 3.8 nM at α 3 , and 2.5 nM at α 5 , whereas it shows ( ) values of (4%) at α 1 , 59 nM (17%) at α 2 , 73 nM (40%) at α 3 , and 44 nM (41%) at α 5 . Based on animal studies, this is expected to translate into a profile of anxiolytic effects with low propensity for sedation.

Clinical findings of NS-11821 in humans have been described. NS-11821 was under development by NeuroSearch. It reached phase 1 clinical trials for both anxiety disorders and CNS disorders prior to the discontinuation of its development in 2017.

The chemical structure of NS-11821 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1357954390 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.